- $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program - AUSTIN, Texas , May 05, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced
- Q&A Session at Conference on Wednesday, April 27 th at 1:30PM Eastern - AUSTIN, Texas , April 25, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the
– All Stakeholder Are Welcome to Listen by Webcast – – Event To Be Held Tuesday, April 5 th , 9am ET – AUSTIN, Texas , April 04, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced webcast details for
– CEO Remi Barbier to Discuss Q1 2022 Clinical and Corporate Updates – – Stakeholders Are Invited to Submit Questions via Email – – Fireside Chat Will Be Open to The Public via Webcast – AUSTIN, Texas , March 30, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.
AUSTIN, Texas , Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the year ended December 31, 2021 and provided clinical and business updates.
AUSTIN, Texas , Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that the U.S. Food and Drug Administration ("FDA") denied a Citizen Petition that was filed in August 2021 by an attorney
New website ( www.Rethink-ALZ.com ) is intended to increase visibility and information for potential study participants. Rethink-ALZ.com connects patients with nearest participating clinical site. Phase 3 efficacy studies now in over 25 clinical sites across the country. AUSTIN, Texas , Dec.
Editor-in- Chief States : “After Careful Examination of These Original Material, Neuroscience [Journal] Found No Evidence of Manipulation of the Western Blot Data or Other Figures of This Publication.” Clearance Is From A Neutral Party Who Is Expert In The Field AUSTIN, Texas , Dec.
Second Phase 3 Study is Designed to Evaluate Safety and Efficacy of Simufilam Over 78 Weeks in 1,000 Patients with Alzheimer’s Disease AUSTIN, Texas , Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, announced today it has initiated a second Phase 3
AUSTIN, Texas , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the third quarter ended September 30, 2021 . Net loss for the third quarter ended September 30, 2021
